[Tolerability of imidazole-2-hydroxybenzoate treatment in children with total erythrocytic glucose-6-phosphate dehydrogenase deficiency (Mediterranean Gd variant)].
D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D004361:Drug Tolerance; D005260:Female; D005955:Glucosephosphate Dehydrogenase Deficiency / Q000188:drug therapy*; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007223:Infant; D008297:Male; D012459:Salicylates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
D000900:Anti-Bacterial Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D007093:Imidazoles; D012459:Salicylates; C043292:imidazole-2-hydroxybenzoate
Studio sulla tollerabilità di un trattamento con imidazolo 2-idrossibenzoato in bambini affetti da deficienza eritrocitaria totale di glucosio-6-fosfato deidrogenasi (varietà Gd mediterranea).